Table 1.
ddPCR validation of NGS-identified somatic variants in cfDNA before and after whole genome amplification.
| Patient ID | NGS-identified variants in cfDNA and/or tumor tissue | Unamplified venous cfDNA | WG-RCA venous cfDNA | WG-RCA fingerstick cfDNA |
|---|---|---|---|---|
| CF31 | PIK3CA-E545K | 26.8 ± 2.1 | 19.7 ± 2.5 | 22.4 ± 0.7 |
| KRAS-G12D | 23.0 ± 2.2 | 10.6 ± 0.5 | 31.8 ± 1.4 | |
| CF4 | PIK3CA-N345K | 16.7 ± 1.0 | 14.5 ± 7.0 | 19.0 ± 3.3 |
| ESR1-D538G | 15.0 ± 2.0 | 2.2 ± 2.0 | 23.4 ± 7.0 | |
| ESR1-Y537C | 10.2 ± 1.6 | 11.2 ± 1.2 | 45.9 ± 6.2 | |
| CF22 | PIK3CA-H1047R | 27.9 ± 1.4 | 15.7 ± 0.6 | 8.1 ± 3.1 |
| CF25 | PIK3CA-E545K | 1.2 ± 0.2 | 11.9 ± 0.8 | 0.11 ± 0.04 |
Average mutant allele frequency ±SEM is indicated using data from at least three independent experiments.